Preventive effect of beta-blockers in the development of aortic dilation in giant cell arteritis-related aortitis
Copyright © 2022 Elsevier Inc. All rights reserved..
OBJECTIVES: To analyze whether beta-blockers (BBs), in addition to conventional care, can decrease the risk of aortic dilation in giant-cell arteritis (GCA)-related aortitis.
METHODS: We conducted in a single medical center retrospective study including 65 consecutive patients with GCA-related aortitis who all underwent aortic morphology control during follow-up. The impact of previous cardiovascular (CV) risk factors and/or events on BB prescription and on the risk for new aortic dilation was analyzed using a weighted (8-point maximum) score between 0 (i.e., 0/8 CV risk factors and events) and 1 (i.e., 8/8).
RESULTS: Among the 65 patients with GCA-related aortitis, 15 (23%) were taking BBs before GCA diagnosis and continued them thereafter. The vascular score was significantly higher in patients who received BBs (0.25 [0.125-0.625] vs. 0.125 [0-0.625] in patients without BBs, p < 0.0001). The median follow-up was 91 [25-163] months in GCA patients taking BBs and 61 [14-248] months in patients not taking BBs (p = 0.13). None of the patients taking BBs developed a new aortic dilation, whereas 15 (15/50; 30%) patients not taking BBs did (p = 0.01), as detected at a median time of 38 [6-120] months after the first imaging. Rates of other CV events during follow-up did not differ between the groups (p = 1).
CONCLUSIONS: This study is the first to suggest that BBs in addition to conventional care in patients with GCA-related aortitis may help to prevent the risk of aortic dilation during follow-up. Larger-sized studies are required to confirm these results.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:57 |
|---|---|
| Enthalten in: |
Seminars in arthritis and rheumatism - 57(2022) vom: 16. Dez., Seite 152117 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dumont, Anaël [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Aortic dilation |
|---|
| Anmerkungen: |
Date Completed 22.11.2022 Date Revised 29.11.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.semarthrit.2022.152117 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348495544 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348495544 | ||
| 003 | DE-627 | ||
| 005 | 20231226040356.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.semarthrit.2022.152117 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1161.xml |
| 035 | |a (DE-627)NLM348495544 | ||
| 035 | |a (NLM)36335685 | ||
| 035 | |a (PII)S0049-0172(22)00168-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dumont, Anaël |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Preventive effect of beta-blockers in the development of aortic dilation in giant cell arteritis-related aortitis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.11.2022 | ||
| 500 | |a Date Revised 29.11.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Inc. All rights reserved. | ||
| 520 | |a OBJECTIVES: To analyze whether beta-blockers (BBs), in addition to conventional care, can decrease the risk of aortic dilation in giant-cell arteritis (GCA)-related aortitis | ||
| 520 | |a METHODS: We conducted in a single medical center retrospective study including 65 consecutive patients with GCA-related aortitis who all underwent aortic morphology control during follow-up. The impact of previous cardiovascular (CV) risk factors and/or events on BB prescription and on the risk for new aortic dilation was analyzed using a weighted (8-point maximum) score between 0 (i.e., 0/8 CV risk factors and events) and 1 (i.e., 8/8) | ||
| 520 | |a RESULTS: Among the 65 patients with GCA-related aortitis, 15 (23%) were taking BBs before GCA diagnosis and continued them thereafter. The vascular score was significantly higher in patients who received BBs (0.25 [0.125-0.625] vs. 0.125 [0-0.625] in patients without BBs, p < 0.0001). The median follow-up was 91 [25-163] months in GCA patients taking BBs and 61 [14-248] months in patients not taking BBs (p = 0.13). None of the patients taking BBs developed a new aortic dilation, whereas 15 (15/50; 30%) patients not taking BBs did (p = 0.01), as detected at a median time of 38 [6-120] months after the first imaging. Rates of other CV events during follow-up did not differ between the groups (p = 1) | ||
| 520 | |a CONCLUSIONS: This study is the first to suggest that BBs in addition to conventional care in patients with GCA-related aortitis may help to prevent the risk of aortic dilation during follow-up. Larger-sized studies are required to confirm these results | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Aortic dilation | |
| 650 | 4 | |a Beta-blockers | |
| 650 | 4 | |a Giant cell arteritis | |
| 650 | 4 | |a Large vessel vasculitis | |
| 650 | 4 | |a Prevention | |
| 700 | 1 | |a Labombarda, Fabien |e verfasserin |4 aut | |
| 700 | 1 | |a Gallou, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Deshayes, Samuel |e verfasserin |4 aut | |
| 700 | 1 | |a Nguyen, Alexandre |e verfasserin |4 aut | |
| 700 | 1 | |a Boutemy, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Martin-Silva, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Maigné, Gwénola |e verfasserin |4 aut | |
| 700 | 1 | |a Aouba, Achille |e verfasserin |4 aut | |
| 700 | 1 | |a de Boysson, Hubert |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Seminars in arthritis and rheumatism |d 1971 |g 57(2022) vom: 16. Dez., Seite 152117 |w (DE-627)NLM000215643 |x 1532-866X |7 nnns |
| 773 | 1 | 8 | |g volume:57 |g year:2022 |g day:16 |g month:12 |g pages:152117 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.semarthrit.2022.152117 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 57 |j 2022 |b 16 |c 12 |h 152117 | ||